MADRID, June 23, 2017 /PRNewswire/ --
Adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia(r/r ALL) have a poor prognosis despite intense salvage treatments. Recent reports have shown that Blinatumomab (Blin) can induce high remission rates in these patients. Blin is a bispecific T-cell engager (BiTE®) antibody construct that is
(Logo: http://mma.prnewswire.com/media/524821/EHA_Logo.jpg )
Presenter: Dr Michaela Kotrova
Affiliation: University Hospital Schleswig-Holstein, Kiel, Germany
Topic: T-CELL RECEPTOR ? (TRB) REPERTOIRE CHARACTERISTICS IN RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) ON BLINATUMOMAB TREATMENT
Abstract S803 will be presented by Michaela Kotrova on Sunday, June 25, 08:00 - 09:15 in Room N103.
About the EHA Annual Congress Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.
SOURCE European Hematology Association
Subscribe to our Free Newsletters!
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...View All